22Feb 2023
Median 5‐year outcomes of primary focal irreversible electroporation for localised prostate cancer

Median 5‐year outcomes of primary focal irreversible electroporation for localised prostate cancer

The study evaluated the use of focal irreversible electroporation (IRE) as the primary treatment for localized clinically significant prostate cancer (csPCa) at a median follow-up of 5 years (up to 10 years) and found that it provides acceptable local and distant oncological control with less urinary and sexual toxicity than radical treatment. Two hundred twenty-nine patients were analyzed, and the Kaplan-Meier failure-free survival rates were 91% at 3 years, 84% at 5 years, and 69% at 8 years. Metastasis-free survival was 99.6%, and PCa-specific and overall survival were 100%. Residual csPCa was found in 24% of patients during follow-up biopsy, and MRI showed a complete ablation in 82% of patients. In addition, short-term urinary continence was preserved, and erections sufficient for intercourse decreased by 13% compared to baseline. Longer-term follow-up and external validation of these findings are needed to establish focal IRE as a valid treatment option.

  • #urology

Like

Save

Share